COMMUNIQUÉS West-GlobeNewswire

Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018
28/02/2018
February 28, 2018 is the 11 th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the kidneys NEW HAVEN, [...]
BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
28/02/2018
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today the dosing of the first patient in APeX-S, a long-term safety trial evaluating two dosage [...]
RadNet, Inc. Announces Date of its Fourth Quarter 2017 Financial Results Conference Call
28/02/2018
LOS ANGELES, Feb. 28, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT ), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
28/02/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Solon Eiendom ASA : Key information relating to the cash dividend proposed
28/02/2018
Oslo, 28 February 2018: Solon Eiendom ASA (OSE: SOLON) Dividend amount: NOK 1.15 per share Declared currency: NOK Last day including right: 23 May 2018 Ex-date: 24 May 2018 Record date: 25 May 2018 Payment date: 4 June [...]
Orion's statutory co-operation negotiations completed
28/02/2018
ORION CORPORATION PRESS RELEASE 28 FEBRUARY 2018 at 10.45 Orion's statutory co-operation negotiations completed Orion's co-operation negotiations regarding the laboratory operations of pharmaceutical production, quality [...]
Orphazyme recognizes Rare Disease Day 2018
28/02/2018
Orphazyme A/S Investor news No. 03/2018 Copenhagen, February 28, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases today announced its support [...]
Veritas Pharma Signs Memorandum of Understanding with BioCan Technologies
28/02/2018
VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of [...]
Biohit Group Financial Statement Release 2017
28/02/2018
Biohit Oyj Financial Statement Release, 28 February 2018 at 9:30 am local time (EET) SUMMARY January-December 2017 Net sales grew by 9.6 % compared to 2016 Net sales EUR 9.0 million (EUR 8.2 million) EBITDA EUR 7.9. [...]
Nexstim Plc: Invitation to the Annual General Meeting
28/02/2018
Company announcement, Helsinki, 28 February 2018 at 9:05 AM Nexstim Plc: Invitation to the Annual General Meeting Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a neuromodulation company developing and [...]
Solon Eiendom ASA : All time high results and dividend
28/02/2018
Solon Eiendom achieved all time high NGAAP results with revenue of NOK 1 128 million and EBITDA of NOK 207 million. IFRS operating revenues were also record high with NOK 883 million and an EBITDA of NOK 108 million in [...]
Xbrane Biopharma releases year-end report for 2017
28/02/2018
Press release 2018-02-28 Xbrane Biopharma AB's (publ.) ("Xbrane") year-end report for 2017 is now available on the Company's website, www.xbrane.com . Financial summary fourth quarter 2017 Revenue amounted to SEK 9,535 [...]
NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2017
28/02/2018
Company announcement, Helsinki, 28 February 2018 at 9:00 am NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a neuromodulation company developing and marketing [...]
Terveystalo Plc Financial statements release January 1-December 31, 2017
28/02/2018
Terveystalo Plc Stock Exchange Release 28 February 2018 at 9:00 EET Adjusted EBITDA for the full year 2017 increased by 26.7 per cent year-on-year to EUR 92.4 million (72.9) Highlights of the review period October- [...]
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - December 31, 2017
28/02/2018
Message from the CEO During the last year, IBT passed the most important milestones in the company's history. The company's pharmaceutical candidate, IBP-9414, for the prevention of necrotizing enterocolitis, has in a [...]
U.S. FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia (ALL)
28/02/2018
U.S. FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia (ALL) If approved, Cal-PEG could provide a new PEGylated asparaginase first-line treatment for [...]
On “Grindeks” results in 2017
28/02/2018
Today, on 28 February, the JSC “Grindeks” submitted the non-audited consolidated financial statements of 2017 to “Nasdaq Riga”. Non-audited financial results indicate that in 2017 turnover of the Group was 132.4 million [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
28/02/2018
REGULATED INFORMATION GHENT, Belgium, 28 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
ABLYNX ANNOUNCES CONVERSION OF BONDS
28/02/2018
REGULATED INFORMATION GHENT, Belgium, 28 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that in relation to the €100,000,000, 3.25% Senior Unsecured Convertible Bonds due on 27 May 2020 ( [...]

Pages